2023 Annual Oncology Clinical Practice and Research Summit
RWJBarnabas Health and Rutgers Cancer Institute held its third annual Oncology Clinical Practice and Research Summit on November 10 and November 11, 2023 at the Hyatt Regency of New Brunswick, NJ.
Hear from Some of Our Experts
Dr. Evens' Perspective on the Annual Oncology Clinical Practice and Research Summit
Dr. Andrew Evens discusses the evolution of the Annual Oncology Clinical Practice and Research Summit over the years, as well as the importance of the initiative for continued innovation and collaboration across oncology service lines.
Dr. Capo on the Importance of the Annual Oncology Clinical Practice and Research Summit
Dr. Gerardo Capo discusses cancer innovations, the meaning of collaborative partnerships and the future of patient care.
Dr. Ecker on Striving for Quality Patient Care in Pancreatic Cancer
Dr. Brett Ecker discusses the benefits of leveraging the expertise of specialists across the health system, and how this can help provide improved pancreatic cancer prevention and intervention.
Dr. Eskander on Cancer Clinical Trials and Understanding Barriers in Research
Dr. Miriam Eskander discusses the value of community partnership, the impact of collaboration on patient care, and various barriers to accessing trials such as transportation.
Dr. Haigentz on Transforming Advancements in Oncology with Teamwork and Collaborative Research
Dr. Missak Haigentz discusses important advancements in clinical cancer research through collaboration and various new therapies available to patients.
Dr. Phillips on Improving Patient Access to Novel Therapies
Dr. Adrienne Phillips discusses the importance of CAR T-Cell Therapy for relapsing malignancies, as well as barriers to access this novel therapy.
OncLive Videos
Dr. Lazzaro on Lung Cancer Screening in High-Risk Individuals
Dr. Richard Lazzaro discusses the advantages of standard low-dose computed tomography scans in lung cancer screening in high-risk individuals, as well as future opportunities to integrate biomarker-based assays into screening protocols to improve early detection.
Dr. Haffty on Technical and Biological Advancements in Radiotherapy Within Breast Cancer
Dr. Bruce Haffty discusses the significance of technical and biological advancements in approaches to radiotherapy, and how they engendered the de-escalation of radiotherapy for select patients with breast cancer.
Dr. Ecker on the Investigation of the Microbiome in Pancreatic Cancer
Dr. Brett Ecker discusses the evaluation of the microbiome in pancreatic cancer, highlighting remaining questions and future steps for research.
Dr. In on Addressing Disparities in Patient Outcomes in Gastric Cancer
Dr. Haejin In discusses the increased incidence of gastric cancer in minority patient populations, highlighting the disparities that lead to these patient outcomes in the United States.
Dr. In on the Importance of Early Cancer Prevention Strategies in Gastric Cancer
Dr. Haejin In discusses the importance of identifying individuals at high risk for developing gastric cancer, specifically those in minority patient populations in the United States (US).
Dr. Phillips on the Management of Toxicities Associated With CAR T-Cell Therapy
Dr. Adrienne Phillips discusses the management of toxicities associated with CAR T-cell therapy across hematologic malignancies.
Dr. Phillips on the Shifting Treatment Paradigm For CAR T-Cell Therapy in LBCL
Dr. Adrienne Phillips discusses the impact of CAR T-cell therapy on the treatment paradigm for patients with large B-cell lymphoma, highlighting key advancements in the decision-making process for CAR T-cell therapy selection.
Dr. Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr. Patrick Boland discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.
Dr. Habib on Developments in Palliative Care For Patients With Cancer
Dr. M. Hamza Habib discusses the development of novel technology-based strategies to improve palliative cancer for patients with cancer.
Dr. Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr. Shridar Ganesan discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.
Looking for videos from past events? Browse our collection of resources from past Annual Oncology Clinical Practice and Research Summits.